CEPI establishes centralised COVID-19 vaccine evaluation network
Five labs have been selected by the Coalition for Epidemic Preparedness Innovations (CEPI) to act as a global network for the assessment of COVID-19 vaccine immunogenicity.
List view / Grid view
Five labs have been selected by the Coalition for Epidemic Preparedness Innovations (CEPI) to act as a global network for the assessment of COVID-19 vaccine immunogenicity.
Italy and India were found to be the only countries to have improved their pharma economy score in 2020, according to the CPhI Pharma Index.
Warnings about addiction will be added to the patient information leaflets of opioids, the MHRA has announced.
Jasper Bovenberg and colleagues argue that the General Data Protection Regulation (GDPR) and associated guidelines has frustrated COVID-19 research, potentially harming global pandemic response efforts.
New research suggests male predominance in COVID-19 expert groups and task forces is undermining the pandemic response.
The WHO has said that the Access to COVID-19 Tools Accelerator will receive almost $1 billion of funding to boost access to tests, treatments and vaccines.
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
Helen Farr, a Partner at Taylor Wessing, discusses the hurdles that life science businesses must tackle to bring employees back to work safely; whether that be working remotely or returning to the lab.
The Access to COVID-19 Tools (ACT) Accelerator reports that new agreements have made millions of rapid COVID-19 antigen tests available to low and middle-income countries.
Due to the demand caused by the COVID-19 pandemic, the UK government has said British manufacturers will produce the majority of PPE by the end of the year.
Researchers suggest, based on certain exclusions, older people are likely to be underrepresented in 50 percent of COVID-19 trials and all vaccine trials in the US.
A review suggests some large pharma companies were approved to receive paycheck protection program (PPP) loans that were intended to help small US businesses to pay workers during the COVID-19 pandemic.
A report has said that the highly potent compound market will grow to be worth $32,200 million by the end of 2026.
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
Growth in the anti-counterfeit technologies market will be particularly large in the pharma industry due to increasing awareness around health and safety, says report.